Abstract
Severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) infection, which causes coronavirus disease 2019 (COVID-19), has led to many cases and deaths worldwide. Therefore, a number of vaccine candidates have been developed to control the COVID-19 pandemic. Of these, to date, 21 vaccines have received emergency approval for human use in at least one country. However, the recent global emergence of SARS-CoV-2 variants has compromised the efficacy of the currently available vaccines. To protect against these variants, the use of vaccines that modulate T cell-mediated immune responses or innate immune cell memory function, termed trained immunity, is needed. The major advantage of a vaccine that uses bacteria or viral systems for the delivery of COVID-19 antigens is the ability to induce both T cell-mediated and humoral immune responses. In addition, such vaccine systems can also exert off-target effects via the vector itself, mediated partly through trained immunity; compared to other vaccine platforms, suggesting that this approach can provide better protection against even vaccine escape variants. This review presents the current status of the development of COVID-19 vaccines based on recombinant viral and bacterial delivery systems. We also discuss the current status of the use of licensed live vaccines for other infections, including BCG, oral polio and MMR vaccines, to prevent COVID-19 infections.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.Avoid common mistakes on your manuscript.
References
Abdulla, Z.A., Al-Bashir, S.M., Al-Salih, N.S., Aldamen, A.A., and Abdulazeez, M.Z. 2021. A summary of the SARS-CoV-2 vaccines and technologies available or under development. Pathogens 10, 788.
Agrawal, B. 2019. Heterologous immunity: role in natural and vaccine-induced resistance to infections. Front. Immunol. 10, 2631.
Altenburg, A.F., Kreijtz, J.H.C.M., De Vries, R.D., Song, F., Fux, R., Rimmelzwaan, G.F., Sutter, G., and Volz, A. 2014. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6, 2735–2761.
Álvarez-Argüelles, M.E., Rojo-Alba, S., Martínez, Z.P., Negredo, Á.L., Riveiro, J.A.B., Álvarez, M.A.A., Súarez, J.R., de Oña Navarro, M., and García, S.M. 2018. New clinical and seasonal evidence of infections by Human Parainfluenzavirus. Eur. J. Clin. Microbiol. Infect. Dis. 37, 2211–2217.
An, D., Li, K., Rowe, D.K., Diaz, M.C.H., Griffin, E.F., Beavis, A.C., Johnson, S.K., Padykula, I., Jones, C.A., Briggs, K., et al. 2021. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine. Sci. Adv. 7, eabi5246.
Anbarasu, A., Ramaiah, S., and Livingstone, P. 2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality? Hum. Vaccin. Immunother. 16, 2217–2218.
Andersen, A., Fisker, A.B., Rodrigues, A., Martins, C., Ravn, H., Lund, N., Biering-Sørensen, S., Benn, C.S., and Aaby, P. 2018. National immunization campaigns with oral polio vaccine reduce all-cause mortality: a natural experiment within seven randomized trials. Front. Public Health 6, 13.
Bache, B.E., Grobusch, M.P., and Agnandji, S.T. 2020. Safety, immunogenicity and risk-benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions. Future Microbiol. 15, 85–106.
Barría, M.I., Garrido, J.L., Stein, C., Scher, E., Ge, Y., Engel, S.M., Kraus, T.A., Banach, D., and Moran, T.M. 2013. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J. Infect. Dis. 207, 115–124.
Barry, M.A., Barry, M., Parrett, B., Lu, S.C., Zell, B., and Matchett, W. 2020. Single-cycle adenoviruses (SC-Ads) as platforms for immunostimulation. J. Immnol. 204, Supplement 166.30.
Basak, P., Sachdeva, N., and Dayal, D. 2021. Can BCG vaccine protect against COVID-19 via trained immunity and tolerogenesis? BioEssays 43, e2000200.
Bezbaruah, R., Borah, P., Kakoti, B.B., Al-Shar’I, N.A., Chandrasekaran, B., Jaradat, D.M.M., Al-Zeer, M.A., and Abu-Romman, S. 2021. Developmental landscape of potential vaccine candidates based on viral vector for prophylaxis of COVID-19. Front. Mol. Biosci. 8, 635337.
Bull, J.J., Nuismer, S.L., and Antia, R. 2019. Recombinant vector vaccine evolution. PLoS Comput. Biol. 15, e1006857.
Capone, S., Raggioli, A., Gentile, M., Battella, S., Lahm, A., Sommella, A., Contino, A.M., Urbanowicz, R.A., Scala, R., and Barra, F. 2021. Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19. Mol. Ther. 29, 2412–2423.
Case, J.B., Rothlauf, P.W., Chen, R.E., Kafai, N.M., Fox, J.M., Smith, B.K., Shrihari, S., McCune, B.T., Harvey, I.B., Keeler, S.P., et al. 2020. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe 28, 465–474.
Chamekh, M. 2015. Genetically engineered bacteria in gene therapy—hopes and challenges. In Hashad, D. (ed.), Gene Therapy—Principles and Challenges. IntechOpen, Rijeka, Croatia. doi: 10.5772/61042. Available from: https://www.intechopen.com/chapters/48719.
Chen, Z., Gupta, T., Xu, P., Phan, S., Pickar, A., Yau, W., Karls, R.K., Quinn, F.D., Sakamoto, K., and He, B. 2015. Efficacy of parainfluenza virus 5 (PIV5)-based tuberculosis vaccines in mice. Vaccine 33, 7217–7224.
Chin’ombe, N. 2013. Recombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag. Viruses 5, 2062–2078.
Choi, Y. and Chang, J. 2013. Viral vectors for vaccine applications. Clin. Exp. Vaccine Res. 2, 97–105.
Clark-Curtiss, J.E. and Curtiss, R. 2018. Salmonella vaccines: conduits for protective antigens. J. Immunol. 200, 39–48.
Comunale, B.A., Engineer, L., Jiang, Y., Andrews, J.C., Liu, Q., Ji, L., Yurkovich, J.T., Comunale, R.A., and Xie, Q. 2021. Poliovirus vaccination induces a humoral immune response that cross reacts with SARS-CoV-2. Front. Med. 8, 710010.
Covián, C., Fernández-Fierro, A., Retamal-Díaz, A., Díaz, F.E., Vasquez, A.E., Lay, M.K., Riedel, C.A., González, P.A., Bueno, S.M., and Kalergis, A.M. 2019. BCG-induced cross-protection and development of trained immunity: implication for vaccine design. Front. Immunol. 10, 2806.
Covián, C., Ríos, M., Berríos-Rojas, R.V., Bueno, S.M., and Kalergis, A.M. 2021. Induction of trained immunity by recombinant vaccines. Front. Immunol. 11, 611946.
Crosby, C.M., Nehete, P., Sastry, K.J., and Barry, M.A. 2015. Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines. J. Virol. 89, 669–675.
Detmer, A. and Glenting, J. 2006. Live bacterial vaccines-a review and identification of potential hazards. Microb. Cell Fact. 5, 23.
Dolzhikova, I.V., Gushchin, V.A., Shcheblyakov, D.V., Tsybin, A.N., Shchetinin, A.M., Pochtovyi, A.A., Komissarov, A.B., Kleymenov, D.A., Kuznetsova, N.A., Tukhvatulin, A., et al. 2021. One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow. medRxiv. doi: https://doi.org/10.1101/2021.10.08.21264715.
Falsey, A.R., Sobieszczyk, M.E., Hirsch, I., Sproule, S., Robb, M.L., Corey, L., Neuzil, K.M., Hahn, W., Hunt, J., Mulligan, M.J., et al. 2021. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N. Eng. J. Med. 385, 2348–2360.
FDA, US Food and Drug Administration. 2021. Shingrix. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/shingrix.
Feldman, K.A., Enscore, R.E., Lathrop, S.L., Matyas, B.T., McGuill, M., Schriefer, M.E., Stiles-Enos, D., Dennis, D.T., Petersen, L.R., and Hayes, E.B. 2001. An outbreak of primary pneumonic tularemia on Martha’s Vineyard. N. Eng. J. Med. 345, 1601–1606.
Francis, A.I., Ghany, S., Gilkes, T., and Umakanthan, S. 2021. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad. Med. J. In press. doi: https://doi.org/10.1136/postgradmedj-2021-140654.
Frantz, P.N., Teeravechyan, S., and Tangy, F. 2018. Measles-derived vaccines to prevent emerging viral diseases. Microbes Infect. 20, 493–500.
Gallo, O., Locatello, L.G., Mazzoni, A., Novelli, L., and Annunziato, F. 2021. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunol. 14, 305–316.
García-Arriaza, J., Garaigorta, U., Pérez, P., Lázaro-Frías, A., Zamora, C., Gastaminza, P., Del Fresno, C., Casasnovas, J.M., Sorzano, C.Ó.S., Sancho, D., et al. 2021. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike protein induce robust T-and B-cell immune responses and full efficacy in mice. J. Virol. 95, e02260–20.
Gold, J.E., Baumgartl, W.H., Okyay, R.A., Licht, W.E., Fidel, P.L. Jr, Noverr, M.C., Tilley, L.P., Hurley, D.J., Rada, B., and Ashford, J.W. 2020. Analysis of measles-mumps-rubella (MMR) titers of recovered COVID-19 patients. mBio 11, e02628–20.
Goodridge, H.S., Ahmed, S.S., Curtis, N., Kollmann, T.R., Levy, O., Netea, M.G., Pollard, A.J., van Crevel, R., and Wilson, C.B. 2016. Harnessing the beneficial heterologous effects of vaccination. Nat. Rev. Immunol. 16, 392–400.
Grifoni, A., Sidney, J., Vita, R., Peters, B., Crotty, S., Weiskopf, D., and Sette, A. 2021. SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19. Cell Host Microbe 29, 1076–1092.
Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings, S.A., Sutherland, A., Premkumar, L., Jadi, R.S., et al. 2020. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501.
Groisman, E.A., Chiao, E., Lipps, C.J., and Heffron, F. 1989. Salmonella typhimurium phoP virulence gene is a transcriptional regulator. Proc. Natl. Acad. Sci. USA 86, 7077–7081.
Gyssens, I.C. and Netea, M.G. 2019. Heterologous effects of vaccination and trained immunity. Clin. Microbiol. Infect. 25, 1457–1458.
Heppner, D.G. Jr, Kemp, T.L., Martin, B.K., Ramsey, W.J., Nichols, R., Dasen, E.J., Link, C.J., Das, R., Xu, Z.J., Sheldon, E.A., et al. 2017. Safety and immunogenicity of the rVSVΔ G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect. Dis. 17, 854–866.
Ho, D.T., Hatabu, T., Sunada, Y., and Kondo, Y. 2020. Oral administration of the probiotic bacterium Lactobacillus acidophilus strain L-55 modulates the immunological parameters of the laying hen inoculated with a Newcastle disease virus-based live attenuated vaccine. Biosci. Microbiota Food Health 39, 117–122.
Hörner, C., Schürmann, C., Auste, A., Ebenig, A., Muraleedharan, S., Dinnon, K.H., Scholz, T., Herrmann, M., Schnierle, B.S., Baric, R.S., et al. 2020. A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine. Proc. Natl. Acad. Sci. USA 117, 32657–32666.
Hu, Z., Ni, J., Cao, Y., and Liu, X. 2020. Newcastle disease virus as a vaccine vector for 20 years: a focus on maternally derived antibody interference. Vaccines 8, 222.
Huang, Y., Yang, C., Xu, X., Xu, W., and Liu, S. 2020. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol. Sin. 41, 1141–1149.
Jakhmola, S., Baral, B., and Jha, H.C. 2021. A comparative analysis of COVID-19 outbreak on age groups and both the sexes of population from India and other countries. J. Infect. Dev. Ctries. 15, 333–341.
Jia, Q., Bielefeldt-Ohmann, H., Maison, R.M., Masleša-Galić, S., Cooper, S.K., Bowen, R.A., and Horwitz, M.A. 2021. Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters. npj Vaccines 6, 47.
Jia, Q., Lee, B.Y., Bowen, R., Dillon, B.J., Som, S.M., and Horwitz, M.A. 2010. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infect. Immun. 78, 4341–4355.
Jia, Q., Lee, B.Y., Clemens, D.L., Bowen, R.A., and Horwitz, M.A. 2009. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis. Vaccine 27, 1216–1229.
Jones, I. and Roy, P. 2021. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet 397, 642–643.
Kim, B.J., Jeong, H., Seo, H., Lee, M.H., Shin, H.M., and Kim, B.J. 2021. Recombinant Mycobacterium paragordonae expressing SARS-CoV-2 receptor-binding domain as a vaccine candidate against SARS-CoV-2 infections. Front. Immunol. 12, 712274.
Kim, B.J., Kim, B.R., Kook, Y.H., and Kim, B.J. 2017. A temperature sensitive Mycobacterium paragordonae induces enhanced protective immune responses against mycobacterial infections in the mouse model. Sci. Rep. 7, 15230.
Kim, B.J., Kim, B.R., Kook, Y.H., and Kim, B.J. 2019. Potential of recombinant Mycobacterium paragordonae expressing HIV-1 Gag as a prime vaccine for HIV-1 infection. Sci. Rep. 9, 15515.
Koonpaew, S., Kaewborisuth, C., Srisutthisamphan, K., Wanitchang, A., Thaweerattanasinp, T., Saenboonrueng, J., Poonsuk, S., Jengarn, J., Viriyakitkosol, R., Kramyu, J., et al. 2021. A single-cycle influenza a virus-based SARS-CoV-2 vaccine elicits potent immune responses in a mouse model. Vaccines 9, 850.
Ku, M.W., Authié, P., Nevo, F., Souque, P., Bourgine, M., Romano, M., Charneau, P., and Majlessi, L. 2021a. Lentiviral vector induces high-quality memory T cells via dendritic cells transduction. Commun. Biol. 4, 713.
Ku, M.W., Bourgine, M., Authié, P., Lopez, J., Nemirov, K., Moncoq, F., Noirat, A., Vesin, B., Nevo, F., Blanc, C., et al. 2021b. Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host Microbe 29, 236–249.
Kumar, A., Misra, S., Verma, V., Vishwakarma, R.K., Kamal, V.K., Nath, M., Prakash, K., Upadhyay, A.D., and Sahu, J.K. 2020. Global impact of environmental temperature and BCG vaccination coverage on the transmissibility and fatality rate of COVID-19. PLoS ONE 15, e0240710.
Li, M., Guo, J., Lu, S., Zhou, R., Shi, H., Shi, X., Cheng, L., Liang, Q., Liu, H., Wang, P., et al. 2021a. Single-dose immunization with a chimpanzee adenovirus-based vaccine induces sustained and protective immunity against SARS-CoV-2 infection. Front. Immunol. 12, 697074.
Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., and Zhou, Q. 2021b. A comprehensive review of the global efforts on COVID-19 vaccine development. ACS Cent. Sci. 7, 512–533.
Lin, I.Y., Van, T.T.H., and Smooker, P.M. 2015. Live-attenuated bacterial vectors: tools for vaccine and therapeutic agent delivery. Vaccines 3, 940–972.
Liu, R., Americo, J.L., Cotter, C.A., Earl, P.L., Erez, N., Peng, C., and Moss, B. 2021. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection. Proc. Natl. Acad. Sci. USA 118, e2026785118.
Loes, A.N., Gentles, L.E., Greaney, A.J., Crawford, K.H.D., and Bloom, J.D. 2020. Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice. Viruses 12, 987.
Logunov, D.Y., Dolzhikova, I.V., Shcheblyakov, D.V., Tukhvatulin, A.I., Zubkova, O.V., Dzharullaeva, A.S., Kovyrshina, A.V., Lubenets, N.L., Grousova, D.M., Erokhova, A.S., et al. 2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671–681.
Lu, M., Dravid, P., Zhang, Y., Trivedi, S., Li, A., Harder, O., Mahesh, K., Chaiwatpongsakorn, S., Zani, A., Kenney, A., et al. 2021. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc. Natl. Acad. Sci. USA 118, e2026153118.
Lundberg, L., Bygdell, M., von Feilitzen, G.S., Woxenius, S., Ohlsson, C., Kindblom, J.M., and Leach, S. 2021. Recent MMR vaccination in health care workers and Covid-19: a test negative case-control study. Vaccine 39, 4414–4418.
Marín-Hernández, D., Nixon, D.F., and Hupert, N. 2021. Heterologous vaccine interventions: boosting immunity against future pandemics. Mol. Med. 27, 54.
Mascellino, M.T., Di Timoteo, F., De Angelis, M., and Oliva, A. 2021. Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infect. Drug Resist. 14, 3459–3476.
Mendonça, S.A., Lorincz, R., Boucher, P., and Curiel, D.T. 2021. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. npj Vaccines 6, 97.
Methner, U., Barrow, P.A., Gregorova, D., and Rychlik, I. 2004. Intestinal colonisation-inhibition and virulence of Salmonella phoP, rpoS and ompC deletion mutants in chickens. Vet. Microbiol. 98, 37–43.
Moradi-Kalbolandi, S., Majidzadeh-A, K., Abdolvahab, M.H., Jalili, N., and Farahmand, L. 2021. The role of mucosal immunity and recombinant probiotics in SARS-CoV2 vaccine development. Probiotics Antimicrob. Proteins 13, 1239–1253.
Motin, V.L. and Torres, A.G. 2009. Molecular approaches to bacterial vaccines. In Barrett, A.D.T. and Stanberry, L.R. (eds.), Vaccines for biodefense and emerging and neglected diseases, 1st edn., pp. 63–76. Academic Press, Amsterdam, The Netherland.
Nagy, A. and Alhatlani, B. 2021. An overview of current COVID-19 vaccine platforms. Comput. Struct. Biotechnol. J. 19, 2508–2517.
Nascimento, L.V., Santos, C.C., Leite, L.C., and Nascimento, I.P. 2020. Characterisation of alternative expression vectors for recombinant Bacillus Calmette-Guérin as live bacterial delivery systems. Mem. Inst. Oswaldo Cruz 115, e190347.
Netea, M.G., Domínguez-Andrés, J., Barreiro, L.B., Chavakis, T., Divangahi, M., Fuchs, E., Joosten, L.A., van der Meer, J.W., Mhlanga, M.M., Mulder, W.J., et al. 2020a. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375–388.
Netea, M.G., Giamarellos-Bourboulis, E.J., Domínguez-Andrés, J., Curtis, N., van Crevel, R., van de Veerdonk, F.L., and Bonten, M. 2020b. Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell 181, 969–977.
Netea, M.G., Joosten, L.A., Latz, E., Mills, K.H., Natoli, G., Stunnenberg, H.G., O’Neill, L.A., and Xavier, R.J. 2016. Trained immunity: a program of innate immune memory in health and disease. Science 352, aaf1098.
Nielsen, S., Khalek, M.A., Benn, C.S., Aaby, P., and Hanifi, S.M.A. 2021a. National immunisation campaigns with oral polio vaccine may reduce all-cause mortality: analysis of 2004–2019 demographic surveillance data in rural Bangladesh. EClinicalMedicine 36, 100886.
Nielsen, S., Sujan, H.M., Benn, C.S., Aaby, P., and Hanifi, S.M.A. 2021b. Oral Polio vaccine campaigns may reduce the risk of death from respiratory infections. Vaccines 9, 1133.
Nieuwenhuizen, N.E., Kulkarni, P.S., Shaligram, U., Cotton, M.F., Rentsch, C.A., Eisele, B., Grode, L., and Kaufmann, S.H. 2017. The recombinant Bacille Calmette-Guérin vaccine VPM1002: ready for clinical efficacy testing. Front. Immunol. 8, 1147.
Nuwarda, R.F., Alharbi, A.A., and Kayser, V. 2021. An overview of influenza viruses and vaccines. Vaccines 9, 1032.
Pasco, S.T. and Anguita, J. 2020. Lessons from Bacillus Calmette-Guérin: harnessing trained immunity for vaccine development. Cells 9, 2109.
Pereira, A.C., Ramos, B., Reis, A.C., and Cunha, M.V. 2020. Non-tuberculous mycobacteria: Molecular and physiological bases of virulence and adaptation to ecological niches. Microorganisms 8, 1380.
Pérez-Girón, J.V., Belicha-Villanueva, A., Hassan, E., Gómez-Medina, S., Cruz, J.L., Lüdtke, A., Ruibal, P., Albrecht, R.A., García-Sastre, A., and Muñoz-Fontela, C. 2014. Mucosal polyinosinic-polycy-tidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity. J. Immunol. 193, 1324–1332.
Rambaut, A., Loman, N., Pybus, O., Barclay, W., Barrett, J., Carabelli, A., Connor, T., Peacock, T., Robertson, D.L., and Volz, E. 2020. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Genom. Epidemiol.https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563/5.
Robert-Guroff, M. 2007. Replicating and non-replicating viral vectors for vaccine development. Curr. Opin. Biotechnol. 18, 546–556.
Roland, K.L. and Brenneman, K.E. 2013. Salmonella as a vaccine delivery vehicle. Expert Rev. Vaccines 12, 1033–1045.
Sánchez-Ramón, S., Conejero, L., Netea, M.G., Sancho, D., Palomares, Ó., and Subiza, J.L. 2018. Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. Front. Immunol. 9, 2936.
Sauer, K. and Harris, T. 2020. An effective COVID-19 vaccine needs to engage T cells. Front. Immunol. 11, 581807.
Shirley, J.L., de Jong, Y.P., Terhorst, C., and Herzog, R.W. 2020. Immune responses to viral gene therapy vectors. Mol. Ther. 28, 709–722.
Silva, A.J., Zangirolami, T.C., Novo-Mansur, M.T.M., Giordano, R.C., and Martins, E.A.L. 2014. Live bacterial vaccine vectors: an overview. Braz. J. Microbiol. 45, 1117–1129.
Steiner, D.J., Furuya, Y., and Metzger, D.W. 2014. Host-pathogen interactions and immune evasion strategies in Francisella tularensis pathogenicity. Infect. Drug Resist. 7, 239–251.
Su, W.J., Chang, C.H., Wang, J.L., Chen, S.F., and Yang, C.H. 2021. Covid-19 severity and neonatal BCG vaccination among young population in Taiwan. Int. J. Environ. Res. Public Health 18, 4303.
Sun, W., Leist, S.R., McCroskery, S., Liu, Y., Slamanig, S., Oliva, J., Amanat, F., Schäfer, A., Dinnon, K.H.3rd, García-Sastre, A., et al. 2020a. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBio-Medicine 62, 103132.
Sun, W., McCroskery, S., Liu, W.C., Leist, S.R., Liu, Y., Albrecht, R.A., Slamanig, S., Oliva, J., Amanat, F., Schäfer, A., et al. 2020b. A Newcastle disease virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. Vaccines 8, 771.
Thysen, S.M., Benn, C.S., Gomes, V.F., Rudolf, F., Wejse, C., Roth, A., Kallestrup, P., Aaby, P., and Fisker, A. 2020. Neonatal BCG vaccination and child survival in TB-exposed and TB-unexposed children: a prospective cohort study. BMJ Open 10, e035595.
Tober, R., Banki, Z., Egerer, L., Muik, A., Behmüller, S., Kreppel, F., Greczmiel, U., Oxenius, A., von Laer, D., and Kimpel, J. 2014. VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. J. Virol. 88, 4897–4907.
Tracker, C.V. 2021. COVID19 vaccine traker. https://covid19.track-vaccines.org/vaccines/. Accessed Oct 2021.
Tscherne, A., Schwarz, J.H., Rohde, C., Kupke, A., Kalodimou, G., Limpinsel, L., Okba, N.M.A., Bošnjak, B., Sandrock, I., Halwe, S., et al. 2021. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination. Proc. Natl. Acad. Sci. USA 118, e2026207118.
Ura, T., Okuda, K., and Shimada, M. 2014. Developments in viral vector-based vaccines. Vaccines 2, 624–641.
Verheust, C., Goossens, M., Pauwels, K., and Breyer, D. 2012. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine 30, 2623–2632.
Vrba, S.M., Kirk, N.M., Brisse, M.E., Liang, Y., and Ly, H. 2020. Development and applications of viral vectored vaccines to combat zoonotic and emerging public health threats. Vaccines 8, 680.
Wang, M., Fu, T., Hao, J., Li, L., Tian, M., Jin, N., Ren, L., and Li, C. 2020. A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2. Int. J. Biol. Macromol. 160, 736–740.
Wang, D., Phan, S., DiStefano, D.J., Citron, M.P., Callahan, C.L., Indrawati, L., Dubey, S.A., Heidecker, G.J., Govindarajan, D., Liang, X., et al. 2017. A single-dose recombinant parainfluenza virus 5-vectored vaccine expressing respiratory syncytial virus (RSV) F or G protein protected cotton rats and African green monkeys from RSV challenge. J. Virol. 91, e00066–17.
WHO, World Health Organizaion. 2021a. The Janssen Ad26.COV2.S COVID-19 vaccine: What you need to know. https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-what-you-need-to-know.
WHO, World Health Organizaion. 2021b. Live Attenuated Vaccines (LAV). https://vaccine-safety-training.org/live-attenuated-vaccines.html. Accessed Oct 2021.
Wibmer, C.K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B.E., De Oliveira, T., Vermeulen, M., Van der Berg, K., et al. 2021. SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 27, 622–625.
Worldometer. 2021. COVID-19 Coronavirus Pandemic. https://www.worldometers.info/coronavirus/.
Xiao, P., Dienger-Stambaugh, K., Chen, X., Wei, H., Phan, S., Beavis, A.C., Singh, K., Deb Adhikary, N.R., Tiwari, P.M., He, B., et al. 2021. Parainfluenza Virus 5 (PIV5) priming followed by SIV/HIV viruslike-particle boosting induces potent and durable immune responses in nonhuman primates. Front. Immunol. 12, 623996.
Yahalom-Ronen, Y., Tamir, H., Melamed, S., Politi, B., Shifman, O., Achdout, H., Vitner, E.B., Israeli, O., Milrot, E., Stein, D., et al. 2020. A single dose of recombinant VSV-ΔG-spike vaccine provides protection against SARS-CoV-2 challenge. Nat. Commun. 11, 6402.
Yang, Y. and Du, L. 2021. SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies. Sig. Transduct. Target. Ther. 6, 95.
Yang, W.T., Yang, G.L., Yang, X., Shonyela, S.M., Zhao, L., Jiang, Y.L., Huang, H.B., Shi, C.W., Wang, J.Z., Wang, G., et al. 2017. Recombinant Lactobacillus plantarum expressing HA2 antigen elicits protective immunity against H9N2 avian influenza virus in chickens. Appl. Microbiol. Biotechnol. 101, 8475–8484.
Yao, Y., Jeyanathan, M., Haddadi, S., Barra, N.G., Vaseghi-Shanjani, M., Damjanovic, D., Lai, R., Afkhami, S., Chen, Y., Dvorkin-Gheva, A., et al. 2018. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell 175, 1634–1650.
Yengil, E., Onlen, Y., Ozer, C., Hambolat, M., and Ozdogan, M. 2021. Effectiveness of booster measles-mumps-rubella vaccination in lower COVID-19 infection rates: a retrospective cohort study in Turkish adults. Int. J. Gen. Med. 14, 1757–1762.
Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y., Duyvesteyn, H.M., Tuekprakhon, A., Nutalai, R., et al. 2021. Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera. Cell 184, 2348–2361.
Zhu, Y., Geng, S., Li, Q., and Jiang, H. 2020a. Transplantation of mesenchymal stem cells: a potential adjuvant therapy for COVID-19. Front. Bioeng. Biotechnol. 8, 557652.
Zhu, D., Meng, Y., Qimuge, A., Bilige, B., Baiyin, T., Temuqile, T., Chen, S., Bao, S., Borjigen, S., Baigude, H., et al. 2020b. Oral delivery of SARS-CoV-2 DNA vaccines using attenuated Salmonella typhimurium} as a carrier in rat. bioRxiv}. doi: https://doi.org/10.1101/2020.07.23.217174.
Zuniga, A., Wang, Z., Liniger, M., Hangartner, L., Caballero, M., Pavlovic, J., Wild, P., Viret, J.F., Glueck, R., Billeter, M.A., et al. 2007. Attenuated measles virus as a vaccine vector. Vaccine 25, 2974–2983.
Acknowledgements
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant No. HV20C0147). The funder was not involved in the analysis, interpretation of data, the writing of this article or the decision for publication.
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflicts of Interest
The authors declare that the article have no potential conflicts of interest to disclose.
Rights and permissions
About this article
Cite this article
Lee, MH., Kim, BJ. COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity. J Microbiol. 60, 321–334 (2022). https://doi.org/10.1007/s12275-022-1621-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-022-1621-2